Insight into the structure and stability of Tc and Re DMSA complexes: A computational study

Abnormal Biologic Distribution Related to Normal Saline Among 99mTc-Dimercaptosuccinic Acid Scans

The primary aim was to describe the incidence and causes of abnormal distribution of ^99mTc-dimercaptosuccinic acid (^99mTc-DMSA) among patients who underwent renal scans in Royal Hospital (Oman) in 2020. The secondary aim was to assess the effect of a specific batch of normal saline A (batch 132129) compared with another normal saline, B (batches 132589 and 133325), used in the preparation of ^99mTc-DMSA on the abnormal biodistribution of ^99mTc-DMSA. Methods: This was an ambidirectional cohort study that included all patients who underwent ^99mTc-DMSA renal scanning between January and December 2020. Both prospective and retrospective data collection was used. The collected data included possible causes of abnormal biodistribution, quality of ^99mTc-DMSA and normal saline, and time of ^99mTc-DMSA injection. Results: The total incidence of abnormal biodistribution was 26.5%, with the most common cause being a high creatinine level (29%). Normal saline batch A was significantly associated with abnormal biodistribution (49.7%), compared with batch B (6.6%) (P < 0.001). This association was more prominent among patients injected with the ^99mTc-DMSA preparation after 2 h (83.0%) compared with before 2 h (13.3%). Conclusion: A high incidence of abnormal biodistribution of ^99mTc-DMSA was detected and-for what is the first time, to our knowledge, in the literature-a specific preservative-free, normal saline that is up to standard has been identified as a significant cause of abnormal biodistribution. Nuclear medicine professionals and pharmaceutical companies should take note of this possible cause of abnormal ^99mTc-DMSA biodistribution.

Radiolysis-Associated Decrease in Radiochemical Purity of 177Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process

The radiolytic degradation of vector molecules is a major factor affecting the shelf life of therapeutic radiopharmaceuticals. The development of time-stable dosage forms of radiopharmaceuticals is the key to their successful implementation in clinical practice. Using [¹⁷⁷Lu]Lu-PSMA-617 molecule as an example, the time dependence of the change in radiochemical purity (RCP, %) under radiolysis conditions was studied. The dependence of [¹⁷⁷Lu]Lu-PSMA-617 radiolysis on parameters such as time, radionuclide activity, buffer agent concentration, precursor amount, and preparation volume was evaluated. It was shown that the absorbed dose was the dominant factor influencing the RCP. The RCP value is inversely proportional to the absorbed dose in the [¹⁷⁷Lu]Lu-PSMA-617 preparation and has an exponential dependence. The lutetium-177 dose factor ψ (Gy·mL·MBq^-1) and PSMA-617 concentration-dependent dose constant κ (Gy^-1) were evaluated for absorbed dose estimation via computer modeling, chemical dosimetry, and radiochemical purity monitoring under various conditions. The further refinement and application of the dependencies found can be useful for predicting the RCP value at the stage of optimizing the composition of the finished dosage form of therapeutic radiopharmaceuticals. The influence of the buffer agent (sodium acetate) concentration on [¹⁷⁷Lu]Lu-PSMA-617 radiolytic degradation was shown and should be considered both when developing a dosage form, and when comparing the results of independent studies. The effectiveness of the addition of various stabilizing agents, such as DMSA, cysteine, gentisic acid, vanillin, methionine, adenine, dobesilic acid, thymine, uracil, nicotinamide, meglumine, and mannitol, in suppressing the effects of radiolysis was evaluated.

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as a result of the growing research interest in personalized medicine to improve diagnostic accuracy and intensify intensive therapy while limiting side effects. Radiometal-based drugs are of substantial interest because of their greater versatility for clinical translation compared to non-metal radionuclides. This paper comprehensively discusses various components commonly used as chemical scaffolds to build radiopharmaceutical agents, i.e., radionuclides, pharmacokinetic-modifying linkers, and chelators, whose characteristics are explained and can be used as a guide for the researcher.

Synthesis, structural characterization, computational studies and stability evaluations of metal ions and ZnONPs complexes with dimercaptosuccinic acid

Meso-2,3-dimercaptosuccinic acid (DMSA) is one of the efficient chelating reagents for treating the toxicity of several heavy metals. Currently, nanomaterial have been applied to various parts including zinc Oxide nanoparticles (ZnONPs). ZnONPs have several properties and are used as many applications. An increasing the amount of ZnONPs in commercial products causes risks related to free radicals or reactive oxygen species (ROS) in the body, leading to oxidative stress and eventually to the cancer process. In the present work, we mainly focused on the study of DMSA complexes in term of metal ions and nanoparticles. The synthesis of DMSA-ZnONPs by the co-precipitation method were determined, followed by Scanning Electron Microscope, Fourier Transform Infrared Spectroscopy and UV-Vis spectrophotometry confirming successful synthesis process. The stability study of the DMSA complexes with metal ions and ZnONPs were determined and evaluated the stability constant (K), with the Benesi- Hildebrand equation. All complexes with DMSA were formed at a 1:2 ratio by the dithiol group and the carboxyl group with different stability constants. Therefore, these results can help of an understanding of the interaction and its behavior between DMSA with heavy metal ion and ZnONPs. In addition, the stable structure of DMSA and metal ion complexes were predicted using the B3LYP and the 6-31G (d,p) basis set which the most stable structure of meso-DMSA was 2R,3S conformation and the metal ions and DMSA complexes was complex 2a with the binding energy of -1553.46 kcal mol^-1.